TGFB1 and Hepatic fibrosis: The underlying mechanism suggests that the combination of gypenosides synergistically shut down the PP2Cα/TGF-β/p65 signaling pathway, thus highlighting the compounds as new therapeutic candidates for the treatment of liver fibrosis.